Background: To present the operative and post-operative comparison between patients who underwent tumor-bed closure with sutures compared with bovine serum albumin-glutaraldehyde (BioGlue) tissue sealant only.
Methods: We retrospectively analyzed data from our ongoing database of 507 eligible patients who underwent open NSS nephron-sparing surgery in our department between January 1995 and May 2014. Patients had tumor-bed closure with sealant adhesive (255 patients) or standard suture technique (252 patients). Demographic, clinical and perioperative data were compared between the two groups, by Chi-square test or by Fisher-Irwin exact test for categorical variables, and by test for differences in means or by Wilcoxon rank sum test for continuous variables. A multivariate analysis was also done.
Results: Patients' baseline characteristics showed similar distribution of the analyzed parameters among both groups, with few differences: younger age in the sealant group (65.4 68.4 years, = 0.01) and slightly larger mass size in the suture group (4.0 3.9 cm, = 0.03). Ischemia time was significantly shorter in the sealant group (21.8 27.0 minutes, = 0001). Blood loss and transfusion rate (0.8% 11.9%, = 0.0001) were significantly less in the sealant group. A multivariate analysis showed date of surgery and blood loss as the major parameters affecting transfusion rate.
Conclusions: Closing the tumor bed with BioGlue tissue adhesive is feasible, safe, can shorten ischemia time and potentially reduce transfusion rate.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5378098 | PMC |
| http://dx.doi.org/10.1177/1756287217697662 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Albumin-based delivery systems: Recent advances, challenges, and opportunities.
J Control Release
January 2025
CÚRAM, SFI Research Centre for Medical Devices, University of Galway, Ireland.
Albumin and albumin-based biomaterials have been explored for various applications, including therapeutic delivery, as therapeutic agents, as components of tissue adhesives, and in tissue engineering applications. It has been approved as an albumin nanoparticle containing paclitaxel (Abraxane®), as an albumin-binding peptide (Victoza®), and as a glutaraldehyde-crosslinked tissue adhesive (BioGlue®). Albumin is also approved as a supportive therapy for various conditions, including hypoalbuminemia, sepsis, and acute respiratory distress syndrome (ARDS).
View Article and Find Full Text PDFFactors Associated With "Sterile Cystic Formation" Following the Application of BioGlue® in Brain Surgery and Review of Literature.
Cureus
December 2024
Emergency Medicine, King Chulalongkorn Memorial Hospital, Bangkok, THA.
Introduction BioGlue® (CryoLife, Inc, Kennesaw, GA), despite being claimed to be a safe and harmless sealant, reportedly has several adverse effects including surgical wound dehiscence. This study aimed to examine the factors that may contribute to this unfavorable outcome in cranial surgery. Methods A retrospective cross-sectional analysis was conducted on patients who underwent brain surgery with the use of BioGlue® between January 2015 and December 2022.
View Article and Find Full Text PDFIn surgery for acute type A aortic dissection, controlling bleeding from the posterior wall of the proximal anastomosis is particularly challenging. To address this, we use the "reversed turn-up technique." For the reinforcement of the proximal aortic stump, Teflon felt strips were placed inside and outside the suture line with 4-0 polypropylene continuous transverse mattress sutures, and BioGlue was applied to the false lumen.
View Article and Find Full Text PDFA 3D bioprinted adhesive tissue engineering scaffold to repair ischemic heart injury.
Biomater Sci
January 2025
Department of Biomedical Engineering, College of Future Technology, Peking University, Beijing 100871, China.
Adhesive tissue engineering scaffold (ATES) devices can be secured on tissues by relying on their intrinsic adhesive properties, hence, avoiding the complications such as host tissue/scaffold damage that are associated with conventional scaffold fixation methods like suturing or bioglue. This study introduces a new generation of three-dimensional (3D) bioprinted ATES systems for use as cardiac patches to regenerate the adult human heart. Tyramine-modified methacrylated hyaluronic acid (HAMA-tyr), gelatin methacrylate (GelMA), and gelatin were used to create the hybrid bioink formulation with self-adhesive properties.
View Article and Find Full Text PDFPolytetrafluoroethylene Felt Inlay Neomedia and Tissue Glue Do Not Prevent Reoperation in Type A Aortic Dissection.
J Clin Med
November 2024
Department of Cardiac Surgery, University Hospital Basel, 4031 Basel, Switzerland.
Type A aortic dissection repair using Polytetrafluorethylene (PTFE) felt inlay and tissue glue has been proposed as a treatment modality. It remains unclear, if this method performs superiorly to tissue glue only. Between January 2011 and December 2015, 139 patients underwent surgical repair for type A aortic dissection, and 48 patients were excluded ( = 29 after receiving a composite graft, = 18 in which no tissue glue was used, and = 1 due to missing data).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!